


PRESS RELEASE

AJJ Medtech and Autagco team up to jointly develop and commercialise Humanoid Elderly Care Robots in Singapore

- *The partnership leverages AJJ's expertise in humanoid robotics and Autagco's experience in elderly care at its assisted living facilities*
- *Collaboration represents launch of the World's First Multi-Functional Humanoid Robot*

SINGAPORE – 13 November 2025 - AJJ Medtech Holdings Limited ("AJJ"), a SGX-listed leading integrated Medtech solutions provider and Autagco Limited ("Autagco"), a SGX-listed assisted living services provider are pleased to announce that both parties have entered into a legally binding Strategic Cooperation Memorandum of Understanding ("MOU") to jointly develop, deploy and commercialise Humanoid Elderly Care Robots within Autagco's assisted living facilities in Singapore.



This strategic partnership leverages AJJ's expertise in humanoid robotics, artificial intelligence and digital health solutions, as well as Autagco's operational expertise in elderly care. The collaboration aims to transform Autagco's assisted living facilities into AI-powered intelligent care environments, providing a model for scalable, high-quality elderly care services.

Following AJJ's announcement on SGXNet on 13 October 2025, this collaboration represents the launch of the World's First Multifunctional Humanoid Elderly Care Robot.

The collaboration will start with Autagco acquiring six (6) units of AJJ-HT-X1 Humanoid Elderly Care Robots for deployment across its assisted living facilities. Clinical trials and the operational applications of the robots will be conducted within Autagco's facilities to validate safety, effectiveness, and functional capabilities, such as companionship, rehabilitation assistance, health monitoring, and cognitive interaction.

AJJ Medtech's Executive Director and Group CEO, Ms. Zhao Xin, said "We are pleased to enter into this strategic MOU with Autagco for the clinical trials, which marks the next phase in the development and operation of the world's first multifunctional humanoid robot. We will capitalise on our expertise in digital healthcare, product know-how and understanding of Singapore's healthcare and regulatory requirements to bring this collaboration forward."

Autagco's Executive Chairman and CEO, Mr. Ng Boon Hui, said, "The strategic partnership with AJJ Medtech will elevate Autagco's level of care services, transforming our service delivery model for our assisted living clients. We are excited to work with AJJ Medtech to bring this collaboration into fruition."

As part of the key responsibilities of the partnership, AJJ will be responsible for obtaining regulatory approvals - including registration with Health Sciences Authority ("HSA"), provision of robot hardware and technology, handling of robot imports, data collection and analysis, cybersecurity and liaison with clinical experts.

Autagco will be responsible for providing its assisted living facilities for the clinical trials and deployment of the humanoid robots, reporting to the Ministry of Health ("MOH"), facilitating staff training and operational integration and supporting commercialisation within its facilities.

Both AJJ and Autagco will share necessary resources, liaise with relevant local and international medical and elderly care institution and ensure compliance with all applicable laws and regulations.

In the long run, the cooperation aims to integrate AI-powered humanoid robots into the real-world eldercare scenarios within Autagco's facilities. The clinical trials and deployment within the facilities seek to accelerate product validation, regulatory compliance and operational readiness of the world's first multifunctional humanoid robot. The MOU is valid for 36 months (from 12 Nov 2025) and may be renewed upon mutual agreement.

This media release should be read in conjunction with the announcement issued by AJJ Medtech Holdings Limited via SGXNET on 13 November 2025.

– END –

About AJJ Medtech Holdings Limited (SGX Ticker: 584)

AJJ Medtech Holdings Limited (“**AJJ Medtech**” or the “**Company**”) is a leader in healthcare technology, providing integrated medtech solutions across Singapore and Southeast Asia. The Company delivers a comprehensive product ecosystem that enhances affordability, efficiency, and effectiveness across the patient care pathway, improving the experience for both patients and healthcare practitioners. Supported by a strong foundation and sustained expansion over the past three years, our core business has gained significant market presence and recognition. We have built the AJJ brand to represent potential, capability, and service excellence. Furthermore, we have transformed from a supplier of basic consumables into a provider of comprehensive turnkey solutions, including supply chain management, digital platforms, AI, and robotics for our partners and customers.

AJJ Healthcare Management Pte. Ltd. (“**AJJ Healthcare**”) is a wholly owned subsidiary of AJJ Medtech, established to manage the Group’s healthcare business.

For more information, please refer to: <https://www.ajjmedtech.com.sg/>

Media & Investor Contact Information

August Consulting Pte Ltd

Tel: (65) 6733 8873

Dave Tan, email: davetan@august.com.sg

Joanna Tan, email: joannatan@august.com.sg

This document has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02 SBF Center, Singapore 068914.